Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has been named the recipient of a grant from the Israel Innovation Authority (“IIA”). According to the announcement, the IIA, which is publicly funded and part of Israel’s Ministry of Economy, approved a nondilutive grant covering 66% of the costs of an ILS 3,536,939 project aimed at ramping up Scinai’s new CDMO business unit; the approximate value of the grant is $900,000. The announcement noted that the grant is not subject to repayment or tied to royalty payments of any kind. The company noted that the award was given after intense due diligence by the IIA, which recognized Scinai’s capabilities to fill an underserved need in Israel’s pharmaceutical R&D ecosystem; the IIA also felt that Scinai’s state-of-the-art GMP biologics manufacturing facility and adjacent R&D and QC laboratories, along with its experienced personnel, are in an ideal position to provide key research and development as well as manufacturing services.
The new business unit will be marketed under the brand Scinai Bioservices and will offer manufacturing process development for protein-based drugs, including host cell transfection/transformation; upstream and downstream process development and scale-up; analytical method development; and cGMP manufacturing for clinical trial supplies, including automatic aseptic filling. “I thank the IIA for its support of Scinai’s plans and their concrete belief in the potential of our business to generate value for stakeholders,” said Scinai Immunotherapeutics CEO Amir Reichman in the press release. “This meaningful nondilutive grant, which is not subject to repayment, will not only advance our CDMO business unit but also provide much-needed relief to our financial position, thereby also indirectly helping our R&D business unit’s drive towards developing our innovative NanoAb-based drug pipeline and clearing the path towards developing Scinai into a company that provides significant benefits to the local and global biopharma and biotech industries, as well as to patients and investors.”
To view the full press release, visit https://ibn.fm/MHJAY
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing along with highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products beginning with an innovative nanosized VHH antibody, or NanoAb, pipeline targeting diseases with large unmet medical needs. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN